NRC FORM 591M PAR (4-2008) 10 CFR 2.201	T 1 U.S. NUCLEAR REGULATORY COMMISSION SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION				
LICENSEE/LOCATION INSPECTED: Advanced Isotopes of Idaho P.O. Box 2105 Pocatello, Idaho 83206 Location Inspected: 4968 Rainbow Lane, Chubbuck, Idaho		2. U R 1	NRC/REGIONAL OFFICE	L OFFICE legulatory Commission lar Boulevard	
REPORT NO: 2022	-001 4. LICENSE NUN	ADED	5 DATES C	DF INSPECTION	
030-37048	11-29216-0			24, 2022	
LICENSEE:	11.20210				
Regulatory Commission procedures and represe 1. Based on th 2. Previous vid 3. The violation non-repetitive were satisfied. Non-Cited of the instance of the	inspection certain of your activities, as descorm is a NOTICE OF VIOLATION, which more structured as the structure of the above, from July 23, 2019, to July of radioactive drugs, the licensees to the above, from July 23, 2019, to July of radioactive drugs, the licensees of the above, from July 23, 2019, to July of radioactive drugs, the licensees of the above, from July 23, 2019, to July of radioactive drugs, the licensees of the above, from July 23, 2019, to July of drugs, the licensees of the	tions of your license and observations by entified. Dector as non-cited vien, and the remaining ving requirements are cribed below and/or hay be subject to postensee shall postensee shall postensees shall postensees and postensees and postensees and postensees and postensees and postensees and postensees are compared to perform to the postense and postensees and postensees and postensees and postensees are compared to perform to the postensees are compared to perform a test for geometry and geometry and geometry are to measure the compared to the postense and the postense and the postense and the postense and the postense are compared to the postense and the p	The inspection consisted of the inspector. The inspection the inspector. The inspection the inspector. The inspection in the inspection of the inspector of the	on findings are as follows: because they were self-identified, ement Policy to exercise discretion NRC requirements and are being CFR 19.11. ion to measure the luse, periodically, and appropriate for the use of the domeasure the iodically, and following ate for the use of the domeasure the measure the milliliter vials, which in-99m radioactive drugs.	
I horoby state that will	Licensee's Statement of				
corrective actions is ma	in 30 days, the actions described by me to de in accordance with the requirements of de will be achieved). I understand that no f Printed Name	10 CFR 2.201 (corre	ctive steps already taken, co	orrective steps which will be taken,	
LICENSEE'S REPRESENTATIVE	Catherine Heyneman	·	Digitally signed by Janine F.	3/22/2022	
NRC INSPECTOR	Janine F. Katanic, PhD, CHP	Janine F. Katanic	Katanic Date: 2022.03.22 14:45:07 -05'00'	March 22, 2022	
BRANCH CHIEF	Lizette Roldan-Otero, PhD	Lizette F	oldan-Otero Dat	itally signed by Lizette Roldan-Otero e: 2022.04.30 07:12:32 -05'00'	
NRC FORM 591M PART 1 (Re	Sensitive – Security-Related		S:\DNMS\INMIB\BRANCH FORM	MS\591M FORMS\Part1 Publicly Available.do X Non-Sensitive	

NRC FORM 591M PART 2 (4-2008) 10 CFR 2.201	U.S. NUCLEAR REGULATORY COMMIS SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION					
LICENSEE/LOCATION INSP Advanced Isotopes of Id Location Inspected: 496 Idaho 83202 REPORT NO: 2022-001		2. NRC/REGIONAL OFFICE U.S. Nuclear Regulatory Commission Region IV, 1600 East Lamar Blvd Arlington, Texas 76011-4511				
3. DOCKET NUMBER	4. LICENSE NUMBER	5. DATE OF INSPECTION				
030-37048	11-29216-01MD	January 24, 2022				
dependence tests for passed the test with procedures to speci	is, on January 24, 2022, immediately or its three dose calibrators using ted in no correction factors or adjustments ify that the geometric dependence te	y after the inspection, the licensee performed geometry chnetium-99m in 10 milliliter vials. All three dose calibrators is needed. The licensee committed to updating its policies and est would be performed annually and upon any repair, of the types and sizes of vials and syringes measured by the				

licensee, including for 10 milliliter vials.

License Condition 21 of NRC License 11-29216-01MD, Amendment No. 12, dated October 27, 2020, requires, in part, that the licensee conduct its program in accordance with Application dated November 11, 2015.

Application dated November 11, 2015, states that "We have developed and will implement and maintain written procedures for leak testing that meet the requirements in 10 CFR 30.53, 10 CFR 20.1501, and 10 CFR 20.2103."

Contrary to the above, from July 23, 2019, to January 24, 2022, the licensee failed to develop, implement, and maintain adequate written procedures for leak testing that met the requirements in 10 CFR 30.53, 10 CFR 20.1501, and 10 CFR 20.2103. Specifically, on multiple occasions, the licensee performed leak test analysis determinations for its own licensed sources as well as for licensed sources possessed by its clients and the licensee's written procedures for leak testing, contained in its Policy and Procedure Manual, Section 6.5, "Sealed Source Leak Testing," did not contain adequate steps to assure that: (1) the current counting efficiency was used in its leak test analysis determinations, and (2) the counting efficiency of the instruments was be determined with a standard source of the same radionuclide or one of similar energy characteristics as the source being tested.

This is a Severity Level IV Violation (Section 6.3.d.).

As corrective actions, the licensee ordered additional sources so that it could check the counting efficiency of its instruments with standard sources of the same radionuclides, or sources with similar energy characteristics, as the sources being tested. The licensee also committed to revise its written procedures for leak testing to be consistent with the guidance in Appendix H, "Model Leak Test Program" of NUREG-1556, Vol. 13, Rev. 2., Program-Specific Guidance About Commercial Radiopharmacy Licenses.